The Swedish Multiple Sclerosis Center Art Show is accepting entries for its 4th annual exhibit. Art will be displayed July 6-7 at the Seattle Center Armory.
Who can enter?
The exhibit features art created by people who have been touched by multiple sclerosis (MS). Anyone with a connection to MS--whether diagnosed, family, caregiver, friend or colleague--is welcome and encouraged to enter. Read full guidelines.
What can I enter?
On September 12, 2012, the Food and Drug Administration (FDA) approved teriflunomide for the treatment of multiple sclerosis (MS). Teriflunomide (AUBAGIO) is a once-daily pill for the treatment of relapsing forms of MS. Led by Dr. Lily Jung Henson, the Swedish Neuroscience Institute was among several clinical sites that tested the drug. Results of the research showed that teriflunomide can lessen MS disease activity. Specifically, it behaves similarly to injectable therapies by slowing MS relapse frequency, the rate of disability and MRI activity.
The safety profile, however, is more challenging than ....
There is exciting news from last week’s 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.
ALEMTUZUMAB. 5-year data from a Phase II extension study for alemtuzumab, an intravenously administered monoclonal antibody, showed that the drug:
This is a remarkable agent with excellent activity in MS. Adverse events included immune thrombocytopenic purpura, thyroiditis and anti-glomerular basement membrane disease.
TERIFLUNOMIDE. A Phase III trial of oral teriflunomide in remitting relapsing MS showed:
Side effects were mild and included diarrhea, nausea, liver function abnormalities and hair loss.
Alemtuzumab and teriflunomide are currently in Phase III clinical trials at SNI.
SNI PRESENTATIONS:
